About Moderna
Moderna Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Since its founding in 2010, Moderna has transformed from a research-stage company into a global pharmaceutical powerhouse with one of the most innovative platforms in medicine.
mRNA Technology Platform
Moderna's proprietary mRNA platform enables rapid development of vaccines and therapeutics by instructing cells to produce proteins that prevent or fight disease. The platform's flexibility allows for quick adaptation to new viral variants and disease targets.
COVID-19 Vaccine Success
Moderna's mRNA-1273 (Spikevax) was one of the first COVID-19 vaccines authorized globally in 2020. The vaccine was developed in just 63 days from sequence selection to first human dose, demonstrating the power of mRNA technology.
Pipeline Expansion
Moderna has the largest mRNA pipeline in the industry with candidates targeting respiratory viruses (RSV, flu, combination vaccines), latent viruses (CMV, EBV), cancer (individualized neoantigen therapy), and rare diseases. The company has over 40 programs in development.
Global Reach
Headquartered in Cambridge, Massachusetts, Moderna employs over 5,700 people and has expanded manufacturing capacity globally. The company reported $6.8 billion in revenue in 2023 and continues to invest heavily in R&D.
Leadership
Stéphane Bancel has served as CEO since 2011, leading Moderna from a small startup to a global biotechnology leader. Under his leadership, Moderna delivered one of the world's most effective COVID-19 vaccines.